Agree with you say TT but there is no benefit to current shareholders other putting up the costs of the trial.
Any benefit from the $100 million already sunk by past & existing shareholders will go to the eventual new owners who will most likely pick up a bargain.
Ann: First patient treated in the UK for the TRIPP-FXX study, page-6
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.001(9.09%) |
Mkt cap ! $45.40M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.3¢ | 1.2¢ | $303.5K | 25.08M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000000 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 9786329 | 8 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |